CD34+ hematopoietic progenitor cells enumeration and mononuclear cell count: an experience from a tertiary care centre

Shuaeb Bhat, Saleem Hussain, Huma Noor, Nadeem Shoket


Background: This study was conducted to assess the CD34+ hematopoietic progenitor cells enumeration by flow cytometry and the utility of performing mononuclear cell count before performing the Stem cell enumeration. Collection was done on two consecutive days with CD34+ hematopoietic progenitor cell enumeration of both the samples. Mononuclear cell counts were done in all the patients. The purpose of the study was to do counts directly from the leukapheresis pack and see the reliability of this practice.

Methods: Samples were collected from the leukapheresis pack and subjected to mononuclear cell count and CD34+ hematopoietic progenitor cells enumeration by flow cytometty before harvesting.

Results: A total of 66 samples from 34 patients were taken up for the study. 76.47% of our cases were that of multiple myeloma and 17.64% of the cases were that of non Hodgkin lymphoma and 2.94% cases each of neuroblastoma and Hodgkin lymphoma. It was noted that the mononuclear cell counts correlated well with the CD34+ HPC in most of the cases with MNC being above 4 x 108 per pack per kg body weight in cases where CD34+ HPC counts were more than the desired lower limit of 2 x 106 per pack per kg body weight.

Conclusions: It was observed that flow cytometric enumeration of CD34+ hematopoietic progenitor cells directly from the leukapheresis pack gave satisfactory results even without doing peripheral blood CD34+ HPCs enumeration before leukapheresis. Also, in our study we were able to set a limit of mononuclear Cell at 4 x 108 per pack/kg BW as counts beyond that always correlated with the more accurate flow cytometric method of CD34+ HPC count of more than 2 x106 per pack/kg body weight, therefore acting as a crude method for assessing the mobilization.


CD34+, Hematopoietic progenitor cells, Leukapheresis, Mononuclear cells

Full Text:



Pusic I, DiPersio JF. The use of growth factors in hematopoietic stem cell transplantation. Curr Pharma Design. 2008 Jul 1;14(20):1950-61.

Santos GW. History of bone marrow transplantation. Clin Haematol. 1983;12(3):611-39.

Baldomero H, Gratwohl M, Gratwohl A, Tichelli A,Niederwieser D, Madrigal A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011;46(4):485-501.

Milone G, Leotta S, Indelicato F, Mercurio S, Moschetti G, Di Raimondo F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pre-treatment. Bone Marrow Transplant. 2003;31(9):747-54.

Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant. 2003;31(5):319-29.

To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997 Apr 1;89(7):2233-58.

Sutherland DR, ANDERSON L, KEENEY M, NAYAR R, Chin-Yee IA. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematotherapy. 1996 Jun;5(3):213-26.

Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992;1(4):329-41.

Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Euro cord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-81.

Scott MA, Gordon MY. In search of the haemopoietic stem cell. Br J Haematol. 1995;90(4):738-43.

Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK.Sensitive detection and enumeration of CD34+cells inperipheral and cord blood by flow cytometry. Exp Hematol. 1994;22(10):1003-10.

Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT. Guideline for the flow cytometric enumeration of CD34+haematopoietic stem cells. Prepared by the CD34+haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999;21(5):301-8.

Trebeden-Negre H, Rosenzwajg M, Tanguy ML, Lefrere F, Azar N, Heshmati F, et al. Delayed recovery after autologousperipheral hematopoietic cell transplantation: potential effect of a high number of total nucleated cells in the graft. Transfusion. 2010;50(12):2649-59.

Duncan N, Hewetson M, Powles R, Raje N, Mehta J. Aneconomic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1996;18(6):1175-8.

Fontao-Wendel R, Lazar A, Melges S, Altobeli C, Wendel S. Theabsolute number of circulating CD34+cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother. 1999;8(3):255-62.

Davis BH, Foucar K, Szczarkowski W, Ball E, Witzig T, Foon KA, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry. 1997;30(5):249-63.

Hollingsworth KL, Zimmerman TM, Karrison T, Oliver A,Williams SF. The CD34+cell concentration in peripheral blood predicts CD34+cell yield in the leukapheresis product. Cytotherapy. 1999;1(2):141-6.

Schots R, Van Riet I, Damiaens S, Flament J, Lacor P, StaelensY, et al. The absolute number of circulating CD34+cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Trans. 1996;17(4):509-15.

Michael Keeney, Ian Chin-Yee, Karin Weir, Jan Popma, Rakash Nayar and D. Robert Sutherland. Single Platform Flow Cytometric Absolute CD34+ Cell Counts Based on the ISHAGE Guidelines. Cytometry (Communications in Clinical Cytometry). 1998;34:61-70.

Chen AI, Bains T, Murray S, Knight R, Shoop K, Bubalo J, et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Trans. 2012;47(12):1526-9.

Szmigielska-Kaplon A, Szemraj J, Hamara K, Robak M, WolskaA, Pluta A, et al. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies. Biol Blood Marrow Trans. 2014;20(7):986-91.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-56.

Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16(4):490-9.

Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G,Angell J, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+cells. Biol Blood Marrow Transplant. 2013;19(4):670-5.